✦ LIBER ✦

Redefining High-Risk Prostate Cancer Based on Distant Metastases and Mortality After High-Dose Radiotherapy With Androgen Deprivation Therapy

✍ Scribed by Rahul D. Tendulkar; Chandana A. Reddy; Kevin L. Stephans; Jay P. Ciezki; Eric A. Klein; Arul Mahadevan; Patrick A. Kupelian

Book ID: 118455664
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 382 KB
Volume: 82
Category: Article
ISSN: 0360-3016
DOI: 10.1016/j.ijrobp.2011.04.042

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-Dose Radiotherapy With or Without A

High-Dose Radiotherapy With or Without Androgen Deprivation Therapy for Intermediate-Risk Prostate Cancer: Cancer Control and Toxicity Outcomes

✍ Scott Edelman; Stanley L. Liauw; Peter J. Rossi; Sherrie Cooper; Ashesh B. Jani 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 340 KB

Intermediate- and High-Risk Prostate Can

Intermediate- and High-Risk Prostate Cancer: A Plea for High-Dose, High-Precision Intensity-Modulated Radiotherapy With a Modulated Duration of Androgen Deprivation Therapy

✍ Michel Bolla 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 77 KB

Pretreatment prostate-specific antigen v

Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy

✍ David Palma; Scott Tyldesley; Tom Pickles; for the Prostate Cohort Outcomes Init 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

## Abstract ## BACKGROUND In men with prostate cancer, pretreatment prostate‐specific antigen (PSA) velocity (PSAV) has been demonstrated as a predictor of biochemical and survival outcomes in patients undergoing radical prostatectomy (RP). The utility of pretreatment PSAV in predicting outcomes a

Ten Years Results with High-dose Radioth

Ten Years Results with High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Prostate Cancer: How Curable is T3 Disease?

✍ A. Zapatero; F. Garcia-Vicente; C. Martin de Vidales; I. Fernandez; A. Cruz Cond 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 52 KB

The addition of low-dose-rate brachyther

The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer

✍ Mark Shilkrut; Gregory S. Merrick; P. William McLaughlin; Matthew H. Stenmark; E 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 716 KB

External-Beam Radiation Therapy and High

External-Beam Radiation Therapy and High–Dose Rate Brachytherapy Combined With Long-Term Androgen Deprivation Therapy in High and Very High Prostate Cancer: Preliminary Data on Clinical Outcome

✍ Rafael Martínez-Monge; Marta Moreno; Raquel Ciérvide; Mauricio Cambeiro; José Lu 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 197 KB